Fig. 6: Proportion of participants above the threshold level associated with 67% protection by time from second vaccination/infection.

The threshold level is 107 BAU ml−1 for ChAdOx1, 94 BAU ml−1 for BNT162b2 and 33 BAU ml−1 for unvaccinated. a, In participants without prior infection and vaccinated with ChAdOX1. b, In participants without prior infection and vaccinated with BNT162b2. c, In participants who had natural infection and unvaccinated. Estimates were separated by age, sex and long-term health condition (LTHC). Numbers of participants in each panel are in the order of no-LTHC and LTHC; numbers in brackets represent <40, 40–65 and >65: a, n = 72,121 [4,973, 46,160, 20,988] and 28,518 [2,166, 14,315, 12,037]; b, n = 36,662 [6,650, 14,108, 15,904] and 18,391 [1,800, 6,696, 9,895]; c, n = 2,625 [1,207, 1,243, 175] and 646 [194, 322, 130]. All panels are conditional on participants having antibody response/seroconverting (see the ‘Vaccine non-responders’ section for ChAdOx1 and BNT162b2 and discussion in a previous publication16 for unvaccinated individuals).